Andexanet alfa

Active ingredient description

Andexanet alfa is a recombinant form of human FXa protein that has been modified to lack FXa enzymatic activity. Andexanet alfa is a specific reversal agent for FXa inhibitors. The predominant mechanism of action is the binding and sequestration of the FXa inhibitor. In addition, andexanet alfa has been observed to bind to, and inhibit tissue factor pathway inhibitor (TFPI). Inhibition of TFPI activity can increase tissue factor-initiated thrombin generation inducing a pro-coagulant effect.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
V03AB38 V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AB Antidotes
Discover more medicines within V03AB38

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
ANDEXXA Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
ONDEXXYA Powder for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 1262449-58-0
DrugBank Drug: DB14562
RxNorm Ingredient: 2045114
SNOMED-CT Concept: 783678000
Andexanet alfa (substance)
UNII Identifier: BI009E452R
ANDEXANET ALFA

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.